James J Hsieh
Overview
Explore the profile of James J Hsieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
9089
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xie Y, Sahin M, Sinha S, Wang Y, Nargund A, Lyu Y, et al.
Nat Cancer
. 2022 Feb;
3(2):188-202.
PMID: 35115713
SETD2 is a histone H3 lysine 36 (H3K36) trimethyltransferase that is mutated with high prevalence (13%) in clear cell renal cell carcinoma (ccRCC). Genomic profiling of primary ccRCC tumors reveals...
12.
Sorokina M, Stupichev D, Lyu Y, Ramachandran A, Miheecheva N, Brown J, et al.
Clin Genitourin Cancer
. 2021 Aug;
19(6):e374-e381.
PMID: 34389275
Background: Although there are immune checkpoint inhibitors (ICIs) available for the treatment of renal cell carcinoma (RCC), the utility of PD-L1 detection by immunohistochemistry (IHC) as a predictive biomarker in...
13.
Tanaka K, Yu H, Yang S, Han S, Selcuklu S, Kim K, et al.
Cancer Cell
. 2021 Aug;
39(9):1245-1261.e6.
PMID: 34388376
The clinical success of EGFR inhibitors in EGFR-mutant lung cancer is limited by the eventual development of acquired resistance. We hypothesize that enhancing apoptosis through combination therapies can eradicate cancer...
14.
DiNatale R, Mano R, Makarov V, Rusk N, Drill E, Winer A, et al.
Kidney Cancer J
. 2021 Jul;
19(2):18-23.
PMID: 34316321
Intratumoral genetic heterogeneity (ITH) poses a significant challenge to utilizing sequencing for decision making in the management of cancer. Although sequencing of multiple tumor regions can address the pitfalls of...
15.
Niizuma H, Searleman A, Takeda S, Armstrong S, Park C, Cheng E, et al.
JCI Insight
. 2021 Jun;
6(15).
PMID: 34156981
Taspase1, a highly conserved threonine protease encoded by TASP1, cleaves nuclear histone-modifying factors and basal transcription regulators to orchestrate diverse transcription programs. Hereditary loss-of-function mutation of TASP1 has recently been...
16.
Lee C, Shah A, Rasco D, Rao A, Taylor M, Di Simone C, et al.
Lancet Oncol
. 2021 Jun;
22(7):946-958.
PMID: 34143969
Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune...
17.
18.
Hutson T, Michaelson M, Kuzel T, Agarwal N, Molina A, Hsieh J, et al.
Eur Urol
. 2021 Apr;
80(2):162-170.
PMID: 33867192
Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the...
19.
Nagaratnam N, Delker S, Jernigan R, Edwards T, Snider J, Thifault D, et al.
Structure
. 2021 Mar;
29(8):873-885.e5.
PMID: 33784495
Taspase1 is an Ntn-hydrolase overexpressed in primary human cancers, coordinating cancer cell proliferation, invasion, and metastasis. Loss of Taspase1 activity disrupts proliferation of human cancer cells in vitro and in...
20.
Pachynski R, Kim E, Miheecheva N, Kotlov N, Ramachandran A, Postovalova E, et al.
Clin Cancer Res
. 2021 Mar;
27(12):3478-3490.
PMID: 33771855
Purpose: Multiparametric MRI (mpMRI) has become an indispensable radiographic tool in diagnosing prostate cancer. However, mpMRI fails to visualize approximately 15% of clinically significant prostate cancer (csPCa). The molecular, cellular,...